Common Variable Immunodeficiency Non-Infectious Disease Endotypes Redefined Using Unbiased Network Clustering in...

Area of Science:

• Immunology and Network Medicine
• Analysis of complex non-infectious disease relationships in primary immunodeficiencies.

Background:

• Common variable immunodeficiency (CVID) is increasingly linked to autoimmune and inflammatory conditions.
• Current clinical care for CVID is hindered by the inability to accurately predict non-infectious disease risks.
• Advances in immunophenotyping and genetics have yet to fully address clinical prediction challenges in CVID.

Purpose of the Study:

• To demonstrate the utility of unbiased network clustering for analyzing non-infectious disease outcomes in CVID.
• To identify novel CVID non-infectious endotypes and associated immunophenotypic markers.
• To explore the relationship between non-infectious disease outcomes, identified endotypes, and mortality risk in CVID.

Main Methods:

• Utilized databases from the United States Immunodeficiency Network (USIDNET) and Partners tertiary care network.
• Applied unbiased network clustering to analyze 34 non-infectious disease outcomes in the Partners cohort.
• Employed natural language processing for electronic medical record data at the Partners network.

Main Results:

• Identified distinct CVID non-infectious endotypes: two lymphoproliferative, two autoimmune, and one atopic cluster.
• Discovered novel predictive markers, including low serum C3 (OR 5.1) for lymphoproliferative disease, and confirmed known markers like high IgE (OR 6.5) for atopy.
• Found significant mortality risk associated with specific non-infectious diseases and lymphoproliferative cluster 2 (OR 5.9).

Conclusions:

• Unbiased network clustering can redefine non-infectious disease inter-relationships in CVID, particularly in well-annotated datasets.
• The identified lymphoproliferative, autoimmune, and atopic CVID endotypes offer a framework for future genetic and biomarker discovery.
• These endotypes can facilitate early screening and intervention for CVID patients at high risk of autoimmune and inflammatory progression.